Moderna soars to multi-year highs ahead of pivotal ESMO cancer-vaccine data (174.85 +20.81 / +12.27%)
- Moderna (MRNA) is soaring and breaking out to multi-year highs after announcing that three abstracts involving its individualized mRNA cancer therapy, intismeran autogene, were accepted for presentation at the ESMO Congress 2026 in October.
- The centerpiece will be late-breaking Phase III INTerpath-001 melanoma data showing intismeran plus Merck's (MRK) Keytruda outperformed Keytruda alone on recurrence-free and distant-metastasis-free survival, with the study receiving a high-profile Presidential Symposium slot.
- Investors are betting that the detailed results will confirm a clinically meaningful benefit and support regulatory submissions, potentially positioning intismeran as the first approved personalized mRNA cancer therapy and creating a major revenue source beyond MRNA's respiratory-vaccine franchise.
- The recent rally has also been supported by the positive Phase III topline melanoma results, durable five-year Phase IIb data showing a 49% reduction in recurrence or death, cost controls, and the FDA approval of mFLUSIVA, MRNA's first seasonal influenza vaccine.
- The ESMO announcement strengthens the view that MRNA's mRNA platform can expand beyond infectious diseases into oncology, although the next leg of the move will depend on the magnitude and safety of the detailed data, the regulatory timeline, and MRNA's ability to manufacture individualized treatments efficiently.
